<DOC>
	<DOCNO>NCT00735436</DOCNO>
	<brief_summary>The primary objective study use 24 week survival ass efficacy combination Gliadel follow Avastin irinotecan treatment grade IV malignant glioma patient follow surgical resection . The secondary objective determine progression-free survival follow combination Gliadel follow Avastin irinotecan describe toxicity Gliadel follow Avastin irinotecan .</brief_summary>
	<brief_title>A Study Gliadel Followed Avastin + Irinotecan Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>This phase II study combination Gliadel follow Avastin irinotecan grade IV malignant glioma patient . The study survival toxicity endpoint . Subjects identify investigator patient histologically document grade IV malignant glioma ( glioblastoma multiforme gliosarcoma ) recurrent progressive disease able undergo gross total resection ( GTR ) . Part I : Gliadel wafer- 1-8 wafer inserted time gross total resection . Treatment cycle 42 day length . For patient â‰¥ Grade 1 toxicity allow 84 day prior begin therapy Avastin Irinotecan ( CPT-11 ) . Part II : Avastin Plus Irinotecan ( Cycles 1-12 ) consist follow ( cycle length 6 week ) : - Irinotecan 125 mg/m2 ( take enzyme-inducing anti-epileptic drug ( EIAEDs ) ) 340 mg/m2 ( take EIAEDs ) give every two week day 1 , 15 , 29 , etc . ; - If patient uridine diphosphate ( UDP ) glucuronosyltransferase 1 family , polypeptide A1 ( UGT1A1 ) polymorphism ( 7/7 ) , metabolize irinotecan normally , patient start two dose level reduction ; For patient EIAED , start dose 275 mg/M2 , patient EIAED , start dose 75 mg/M2 ; - Avastin 10 mg/kg immediately irinotecan give every 2 week day 1 , 15 , 29 , etc . The primary objective phase II study determine whether administration Gliadel wafer follow Avastin irinotecan patient recurrent GBM treatment regimen worthy investigation randomize clinical trial . The basis make decision proportion patient survive least 24 week initiation protocol treatment . In initial Phase I II clinical trial , four potential Avastin-associated safety signal identify : hypertension , proteinuria , thromboembolic event , hemorrhage . The two major toxicity associate irinotecan myelosuppression diarrhea . Side effect associate Gliadel seizure , brain edema ( swell ) , heal abnormality , wound infection body pain .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis WHO grade IV primary malignant glioma ( glioblastoma multiforme gliosarcoma ) . Patients able undergo GTR . Age &gt; = 18 year Evidence unilateral , single focus measurable central nervous system ( CNS ) neoplasm contrastenhanced MRI , unless medically contraindicate ( CT scan use ) Patients must &lt; = 2 disease progression An interval least 4 week end prior radiotherapy one week end cycle chemotherapy enrollment protocol Karnofsky &gt; = 70 % Hemoglobin &gt; = 9.0 g/dl , absolute neutrophil count ( ANC ) &gt; = 1,500 cells/microliters , platelet &gt; = 125,000 cells/microliters Serum creatinine &lt; = 1.5 mg/dl , serum glutamicoxaloacetic transaminase ( SGOT ) bilirubin &lt; = 1.5 time upper limit normal Patients corticosteroid must stable dose 1 week prior entry , clinically possible , dose escalated entry dose level If patient receive chemotherapy investigational agent part prior therapy , patient must recover toxicity ( &gt; = Grade 1 ) prior enrollment protocol Signed informed consent approve Institutional Review Board No evidence CNS hemorrhage baseline MRI CT scan If sexually active , patient take contraceptive measure duration treatment state informed consent Pregnancy breast feeding . Women childbearing potential must negative serum pregnancy test within 72 hour prior treatment administration Multifocal disease Prior treatment Gliadel Prior treatment CPT11 Avastin Prior stereotactic radiosurgery brachytherapy Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid Active infection require IV antibiotic Acute chronic renal insufficiency ( glomerular filtration rate ( GFR ) &lt; 30 mL/min/1.73m2 ) acute renal insufficiency severity due hepatorenal syndrome perioperative liver transplantation period Inability , opinion study investigator , comply study and/or followup procedure Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored Avastin cancer study Life expectancy le 12 week Active malignancy , superficial basal cell superficial squamous ( skin ) cell , carcinoma situ cervix within last five year Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg ) Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 History hemoptysis ( &gt; = 1/2 teaspoon bright red blood per episode ) within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula , gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria screening demonstrate urinalysis ( urine protein ) Known hypersensitivity component Avastin Pregnancy ( positive pregnancy test ) lactation . Use effective mean contraception ( men woman ) subject childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Malignant glioma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Gliadel</keyword>
	<keyword>Carmustine</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>CPT-11</keyword>
	<keyword>Camptosar</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>